WHR1

Summary

WHR1 (winged helix repair factor 1, HGNC:11398) is a protein-coding gene on chromosome 6p21.33, encoding Winged helix repair factor 1 (P49842). DNA-binding protein which is required for efficient transcription-coupled nucleotide excision repair (TC-NER).

This gene encodes a serine/threonine kinase which localizes predominantly to the nucleus. Its specific function is unknown; it is possible that phosphorylation of this protein is involved in transcriptional regulation. This gene localizes to the major histocompatibility complex (MHC) class III region on chromosome 6 and expresses two transcript variants.

Source: NCBI Gene 8859 — RefSeq curated summary.

At a glance

• GWAS associations: 45
• Clinical variants (ClinVar): 42 total
• Druggable target: yes
• MANE Select transcript: NM_004197

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11398
Approved symbol	WHR1
Name	winged helix repair factor 1
Location	6p21.33
Locus type	gene with protein product
Status	Approved
Aliases	G11, RP1, D6S60, TWH19
Ensembl gene	ENSG00000204344
Ensembl biotype	protein_coding
OMIM	604977
Entrez	8859

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 12 protein_coding, 8 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000375331, ENST00000375333, ENST00000460018, ENST00000463823, ENST00000466132, ENST00000466336, ENST00000469907, ENST00000471028, ENST00000473983, ENST00000478486, ENST00000479644, ENST00000483801, ENST00000484540, ENST00000490822, ENST00000491861, ENST00000492583, ENST00000519179, ENST00000685781, ENST00000858578, ENST00000923321, ENST00000923322, ENST00000968133, ENST00000968134

RefSeq mRNA: 2 — MANE Select: NM_004197 NM_004197, NM_032454

CCDS: CCDS34417

Canonical transcript exons

ENST00000547578 — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 98.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.8360 / max 119.4819, expressed in 1809 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
67106	8.2116	1782
67107	4.7618	1709
67108	0.8374	313
67109	0.0252	5

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left adrenal gland	UBERON:0001234	98.20	gold quality
left adrenal gland cortex	UBERON:0035825	98.11	gold quality
right adrenal gland	UBERON:0001233	98.02	gold quality
right adrenal gland cortex	UBERON:0035827	97.75	gold quality
adrenal gland	UBERON:0002369	97.51	gold quality
right lobe of liver	UBERON:0001114	94.09	gold quality
skin of leg	UBERON:0001511	93.27	gold quality
adenohypophysis	UBERON:0002196	93.09	gold quality
zone of skin	UBERON:0000014	93.06	gold quality
skin of abdomen	UBERON:0001416	93.04	gold quality
left ovary	UBERON:0002119	93.03	gold quality
pituitary gland	UBERON:0000007	92.89	gold quality
right ovary	UBERON:0002118	92.85	gold quality
spleen	UBERON:0002106	92.65	gold quality
adrenal tissue	UBERON:0018303	92.42	gold quality
metanephros cortex	UBERON:0010533	92.41	gold quality
ovary	UBERON:0000992	92.31	gold quality
left uterine tube	UBERON:0001303	92.07	gold quality
adult mammalian kidney	UBERON:0000082	91.83	gold quality
muscle layer of sigmoid colon	UBERON:0035805	91.74	gold quality
right hemisphere of cerebellum	UBERON:0014890	91.69	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.64	gold quality
lower esophagus	UBERON:0013473	91.63	gold quality
left lobe of thyroid gland	UBERON:0001120	91.43	gold quality
lower esophagus mucosa	UBERON:0035834	91.43	gold quality
right lobe of thyroid gland	UBERON:0001119	91.41	gold quality
cerebellar hemisphere	UBERON:0002245	91.34	gold quality
mucosa of stomach	UBERON:0001199	91.32	gold quality
esophagus mucosa	UBERON:0002469	91.30	gold quality
cerebellar cortex	UBERON:0002129	91.28	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.47

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

24 targeting WHR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-9851-3P	99.63	69.68	1110
HSA-MIR-4663	99.62	65.33	957
HSA-MIR-1911-3P	99.15	66.17	528
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-7843-5P	98.12	65.26	1421
HSA-MIR-4691-3P	98.11	66.83	1204
HSA-MIR-4632-5P	97.82	65.38	1470
HSA-MIR-4660	97.79	67.44	1328
HSA-MIR-6879-5P	97.77	65.52	1521
HSA-MIR-10398-5P	97.12	64.94	1051
HSA-MIR-4462	95.10	66.27	172

Literature-anchored findings (GeneRIF, showing 2)

• STK19: a new target for NRAS-driven cancer. (PMID:32587355)
• STK19 is a DNA/RNA-binding protein critical for DNA damage repair and cell proliferation. (PMID:38252411)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	stk19	ENSDARG00000086628
		ENSDARG00000101693
mus_musculus	Stk19	ENSMUSG00000061207
rattus_norvegicus	Stk19	ENSRNOG00000048929

Protein

Protein identifiers

Winged helix repair factor 1 — P49842 (reviewed: P49842)

Alternative names: Inactive serine/threonine-protein kinase 19, Protein G11, Protein RP1, Tandem winged helix protein formerly known as STK19

All UniProt accessions (5): P49842, A0A1U9X8L3, A0AAQ5BI79, C9J6S8, H0YAS4

UniProt curated annotations — full annotation on UniProt →

Function. DNA-binding protein which is required for efficient transcription-coupled nucleotide excision repair (TC-NER). Acts as part of a TC-NER complex which assembles and interacts with RNA polymerase II (RNAPII) when it stalls at DNA lesions. TC-NER complex subunit UVSSA binds to the GTF2H1/p62 subunit of the TFIIH transcription factor complex, tethering TFIIH to the TC-NER complex. WHR1/STK19 then interacts with the XPD helicase subunit of TFIIH which guides TFIIH to DNA downstream of the stalled RNAPII, ensuring DNA repair. Directly interacts with RNAPII and also binds to downstream DNA. Promotes the timely removal of DNA damage-stalled RNAPII, allowing downstream NER factors to access DNA lesions. Required for monoubiquitination of UVSSA. Regulates repositioning and stabilization of UVSSA within the TC-NER complex. Stimulates ubiquitination of RNAPII complex member RBP1. Also binds to RNA and regulates the expression levels of many mRNAs.

Subunit / interactions. Monomer in solution. Homodimer; when bound to DNA. Component of a transcription-coupled nucleotide excision repair (TC-NER) complex composed of STK19, ERCC6, ERCC8, DDA1, DDB1, ELOF1 and UVSSA which assembles and interacts with the multiprotein RNA polymerase II complex when it stalls at DNA lesions.

Subcellular location. Nucleus Nucleus Nucleus. Cytoplasm.

Tissue specificity. Monocytes, hepatocytes, epithelial cells, T- and B-lymphocytes.

Induction. By ultraviolet radiation (at protein level). Increased by ultraviolet radiation in melanocytes.

Similarity. Belongs to the STK19 family.

Isoforms (4)

UniProt ID	Names	Canonical?
P49842-4	4, G11-Y-short	yes
P49842-1	1, G11-Z
P49842-2	2, G11-Z-short
P49842-3	3, G11-Y

RefSeq proteins (2): NP_004188, NP_115830 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR018865	STK19-like	Family

Pfam: PF10494

UniProt features (54 total): mutagenesis site 18, helix 14, strand 9, sequence variant 4, region of interest 3, turn 2, splice variant 2, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
8YCM	X-RAY DIFFRACTION	1.32
7XRB	X-RAY DIFFRACTION	1.65
9BZ0	ELECTRON MICROSCOPY	1.9
9ER2	ELECTRON MICROSCOPY	3.3
9FD2	ELECTRON MICROSCOPY	3.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P49842-F1	87.02	0.81

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (18):

Position	Phenotype
72–73	reduces ubiquitination of rnapii.
181–182	reduces ubiquitination of rnapii.
186	abolishes dna-binding activity. abolishes dna-binding activity, causes relocalization to the cytoplasm and reduces inter
186	weakly impairs dna repair.
190	abolishes dna-binding activity, causes relocalization to the cytoplasm and reduces interaction with ercc6 and rpa2; when
190	reduces ubiquitination of rnapii and interaction with dna; when associated with d-216.
200–203	abolishes dna-binding activity.
200–201	severely impairs dna repair.
200	does not affect dna repair.
201	dramatically reduces dna-binding activity. abolishes dna-binding activity, causes relocalization to the cytoplasm and re
203–204	reduces ubiquitination of rnapii. reduces interaction with uvssa.
204	reduces self-association and dna-binding activity. increases cytoplasmic localization.
206	increases cytoplasmic localization.
215–216	abolishes dna-binding activity.
216	reduces ubiquitination of rnapii and interaction with dna; when associated with d-190.
248	increases cytoplasmic localization.
250	increases cytoplasmic localization.
4–21	partial reduction in nuclear localization.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 348 (showing top): HARRIS_HYPOXIA, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_PHOTOTRANSDUCTION, GOBP_NEUROGENESIS, FOXO4_01, GOBP_NEURAL_RETINA_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_REGULATION_OF_DNA_REPAIR, MORF_RAF1, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_EYE_PHOTORECEPTOR_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS

GO Biological Process (4): DNA repair (GO:0006281), positive regulation of Ras protein signal transduction (GO:0046579), positive regulation of single strand break repair (GO:1903518), DNA damage response (GO:0006974)

GO Molecular Function (6): double-stranded DNA binding (GO:0003690), double-stranded RNA binding (GO:0003725), protein homodimerization activity (GO:0042803), DNA binding (GO:0003677), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	2
DNA metabolic process	1
DNA damage response	1
Ras protein signal transduction	1
regulation of Ras protein signal transduction	1
positive regulation of small GTPase mediated signal transduction	1
single strand break repair	1
positive regulation of DNA repair	1
regulation of single strand break repair	1
cellular response to stress	1
DNA binding	1
RNA binding	1
identical protein binding	1
protein dimerization activity	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

478 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WHR1	SKIC2	Q15477	896
WHR1	TNXB	P22105	879
WHR1	CYP21A2	P04033	842
WHR1	DXO	O77932	813
WHR1	C4A	P01028	805
WHR1	SNX31	Q8N9S9	697
WHR1	PPP6C	O00743	679
WHR1	C2	P06681	623
WHR1	TACC1	O75410	614
WHR1	C3orf18	Q9UK00	601
WHR1	C4A	P01028	596
WHR1	PRH1	P02810	511
WHR1	ARID2	Q68CP9	479
WHR1	KIR2DL4	P78400	476
WHR1	NRAS	P01111	474

IntAct

27 interactions, top by confidence:

A	B	Type	Score
IMPDH1	BCAT2	psi-mi:“MI:0914”(association)	0.530
WHR1	ASB3	psi-mi:“MI:0915”(physical association)	0.500
WHR1	ACACB	psi-mi:“MI:0914”(association)	0.350
PNMA8A	AP3B1	psi-mi:“MI:0914”(association)	0.350
WHR1	HSPD1	psi-mi:“MI:0914”(association)	0.350
AKT1	WHR1	psi-mi:“MI:2364”(proximity)	0.270
FBXW7	WHR1	psi-mi:“MI:2364”(proximity)	0.270
WHR1	SMARCA4	psi-mi:“MI:2364”(proximity)	0.270
SMARCA4	WHR1	psi-mi:“MI:2364”(proximity)	0.270
SPOP	WHR1	psi-mi:“MI:2364”(proximity)	0.270
WHR1	SPOP	psi-mi:“MI:2364”(proximity)	0.270
EGFR	WHR1	psi-mi:“MI:2364”(proximity)	0.270
WHR1	PTPN11	psi-mi:“MI:2364”(proximity)	0.270
WHR1	TP53	psi-mi:“MI:2364”(proximity)	0.270
WHR1	POLE	psi-mi:“MI:0915”(physical association)	0.000
WHR1	POLR2G	psi-mi:“MI:0915”(physical association)	0.000
WHR1	SF3B4	psi-mi:“MI:0915”(physical association)	0.000
WHR1	SP3	psi-mi:“MI:0915”(physical association)	0.000
WHR1	SLC29A1	psi-mi:“MI:0915”(physical association)	0.000
WHR1	PRAME	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (30): STK19 (Two-hybrid), STK19 (Two-hybrid), POLE (Two-hybrid), POLR2G (Two-hybrid), SLC29A1 (Two-hybrid), PRAME (Two-hybrid), STK19 (Affinity Capture-MS), STK19 (Two-hybrid), STK19 (Proximity Label-MS), STK19 (Two-hybrid), STK19 (Two-hybrid), STK19 (Two-hybrid), STK19 (Two-hybrid), STK19 (Two-hybrid), STK19 (Two-hybrid)

ESM2 similar proteins: A0A0E0SC50, A1CTJ1, A1D4X8, A1DMW6, A2X052, A4D9P4, A4RN19, A6RA46, A7EAE5, A7EGK5, A7KAM3, B4FTR7, B8AK78, F7W503, O35954, O94817, P0CM28, P0CM29, P49842, P62869, P62870, Q01317, Q0JCC3, Q0UNW1, Q10CI8, Q13367, Q15370, Q1DY54, Q1E8C2, Q2GSG9, Q2TBJ5, Q2UMW6, Q2URI8, Q3T0W7, Q42713, Q43307, Q4WKD7, Q51P78, Q5BCH0, Q5R7W1

Diamond homologs: A0A1L8F8I9, P49842, Q9JHN8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
STK19	“up-regulates activity”	NRAS	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1732 predictions. Top by Δscore:

Variant	Effect	Δscore
6:31978881:A:AG	acceptor_gain	1.0000
6:31978892:T:A	acceptor_gain	1.0000
6:31978894:T:TA	acceptor_gain	1.0000
6:31978895:G:A	acceptor_gain	1.0000
6:31978984:GAC:G	donor_gain	1.0000
6:31978997:GA:G	donor_gain	1.0000
6:31978998:AGT:A	donor_loss	1.0000
6:31978999:GT:G	donor_loss	1.0000
6:31978999:GTAT:G	donor_gain	1.0000
6:31979000:T:G	donor_loss	1.0000
6:31979009:GT:G	donor_gain	1.0000
6:31980649:TCTA:T	acceptor_loss	1.0000
6:31980650:CTAG:C	acceptor_loss	1.0000
6:31980651:TAGG:T	acceptor_loss	1.0000
6:31980652:A:AG	acceptor_gain	1.0000
6:31980652:A:AT	acceptor_loss	1.0000
6:31980652:AG:A	acceptor_gain	1.0000
6:31980653:G:GA	acceptor_gain	1.0000
6:31980653:GG:G	acceptor_gain	1.0000
6:31972508:CCAG:C	donor_loss	0.9900
6:31972509:CAG:C	donor_loss	0.9900
6:31972510:AG:A	donor_loss	0.9900
6:31972511:GG:G	donor_loss	0.9900
6:31972513:T:G	donor_loss	0.9900
6:31972754:GCTG:G	donor_gain	0.9900
6:31972783:G:GT	donor_gain	0.9900
6:31978882:C:G	acceptor_gain	0.9900
6:31978901:A:AG	acceptor_gain	0.9900
6:31978902:G:GT	acceptor_gain	0.9900
6:31978992:G:GT	donor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000809916 (6:31973421 A>G), RS1001124485 (6:31975117 C>T), RS1001158549 (6:31980963 G>A), RS1002211315 (6:31976369 G>A), RS1002990582 (6:31971355 C>A,G,T), RS1003118406 (6:31973568 T>G), RS1003126584 (6:31971773 A>C), RS1003165508 (6:31979202 G>A), RS1003322023 (6:31978824 C>G,T), RS1004496496 (6:31976380 C>T), RS1004562112 (6:31977048 A>G), RS1004735121 (6:31975092 A>G), RS1005009927 (6:31977578 G>A,C), RS1005232049 (6:31974513 T>G), RS1006232081 (6:31979840 T>C,G)

Disease associations

OMIM: gene MIM:604977 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

45 associations (top):

Study	Trait	p-value
GCST001779_12	Hematology traits	2.000000e-08
GCST001942_21	Prostate cancer	5.000000e-09
GCST001986_2	Age-related macular degeneration	2.000000e-10
GCST004131_25	Inflammatory bowel disease	2.000000e-31
GCST004133_79	Ulcerative colitis	5.000000e-65
GCST004521_114	Autism spectrum disorder or schizophrenia	3.000000e-17
GCST004521_117	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_118	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_126	Autism spectrum disorder or schizophrenia	2.000000e-10
GCST004521_154	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST004521_162	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST004521_17	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_170	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_173	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_209	Autism spectrum disorder or schizophrenia	5.000000e-16
GCST004521_211	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_213	Autism spectrum disorder or schizophrenia	5.000000e-13
GCST004521_224	Autism spectrum disorder or schizophrenia	5.000000e-10
GCST004521_227	Autism spectrum disorder or schizophrenia	4.000000e-12
GCST004521_296	Autism spectrum disorder or schizophrenia	6.000000e-18
GCST004521_45	Autism spectrum disorder or schizophrenia	2.000000e-16
GCST004521_81	Autism spectrum disorder or schizophrenia	1.000000e-14
GCST005359_2	Disease progression in age-related macular degeneration	8.000000e-10
GCST005541_19	Sarcoidosis (Lofgren’s syndrome vs non-Lofgren’s syndrome)	1.000000e-32
GCST006190_17	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	4.000000e-10
GCST006190_18	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	7.000000e-06
GCST006190_58	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	1.000000e-10
GCST006190_59	Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	1.000000e-09
GCST006192_37	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	3.000000e-14
GCST006192_87	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	4.000000e-11

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0008336	disease progression measurement
EFO:0006336	diastolic blood pressure
EFO:0006527	smoking status measurement
EFO:0006335	systolic blood pressure
EFO:0008039	BMI-adjusted hip circumference
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0007789	BMI-adjusted waist circumference
EFO:0004531	urate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4879437 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs374527	RP1		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — G11 family

ChEMBL bioactivities

25 potent at pChembl≥5 of 25 total, top 25 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.62	IC50	24.04	nM	CHEMBL4870304
7.62	IC50	23.96	nM	CHEMBL4870304
7.55	IC50	27.94	nM	CHEMBL4870304
7.53	IC50	29.33	nM	CHEMBL4866963
7.45	IC50	35.46	nM	CHEMBL4870304
7.32	IC50	48.32	nM	CHEMBL4852690
7.24	IC50	57.12	nM	CHEMBL4849486
7.19	IC50	64.55	nM	CHEMBL4852751
7.16	IC50	70.01	nM	CHEMBL4850497
7.10	IC50	79.88	nM	CHEMBL4867099
7.10	IC50	79.04	nM	CHEMBL4845829
7.04	IC50	90.91	nM	CHEMBL4861911
7.02	IC50	95.6	nM	CHEMBL4870304
7.01	IC50	96.67	nM	CHEMBL4865989
7.00	IC50	98.77	nM	CHEMBL4854631
6.99	IC50	101.7	nM	CHEMBL4866469
6.90	IC50	127.2	nM	CHEMBL4853823
6.86	IC50	137	nM	CHEMBL4869170
6.83	IC50	148.3	nM	CHEMBL4863409
6.77	IC50	169.3	nM	CHEMBL4870304
6.75	IC50	178.2	nM	CHEMBL4852657
6.60	IC50	251.9	nM	CHEMBL4865317
6.49	IC50	322	nM	CHEMBL4870304
6.19	IC50	649.2	nM	CHEMBL4870304
6.17	IC50	680.7	nM	CHEMBL4870304

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	3
Valproic Acid	affects expression, decreases expression, increases expression	3
Tunicamycin	increases expression	2
Cyclosporine	increases expression	2
Thapsigargin	increases expression	2
aristolochic acid I	increases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression	1
nickel sulfate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Ethanol	affects cotreatment, increases abundance, increases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Ethyl Methanesulfonate	increases expression	1
Gasoline	increases expression, affects cotreatment, increases abundance	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	increases expression, affects cotreatment	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1
Smoke	decreases expression	1
Triiodothyronine	increases expression	1

ChEMBL screening assays

36 unique, capped per target: 36 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4805273	Binding	Inhibition of recombinant human STK19 at 10 uM using HA-tagged GTP-preloaded NRAS as substrate incubated for 0-40 mins and measured by ADP-Glo assay relative to control	Stk19 inhibitors for treatment of cancer

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TQ78	HAP1 STK19 (-) 1	Cancer cell line	Male
CVCL_TQ79	HAP1 STK19 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.